Dr. Grey AI

Dulaglutide (Trulicity)

Peptide

Dulaglutide (Trulicity) is a GLP-1 receptor agonist peptide approved by the FDA for type 2 diabetes. It is a fusion protein consisting of two GLP-1 analogs covalently linked to a modified human IgG4-Fc heavy chain, enabling once-weekly dosing. The AWARD clinical trial program demonstrated efficacy for glycemic control, and the REWIND trial showed cardiovascular benefits in a broad population with T2DM.

Quick Answer

What it is

Dulaglutide (Trulicity) is a GLP-1 receptor agonist peptide approved by the FDA for type 2 diabetes. It is a fusion protein consisting of two GLP-1 analogs covalently linked to a modified human IgG4-Fc heavy chain, enabling once-weekly dosing.

Key findings

  • Grade A: HbA1c Reduction (Type 2 Diabetes)
  • Grade A: Glycemic Control (HbA1c <7%) (Type 2 Diabetes)
  • Grade A: Body Weight Reduction (Type 2 Diabetes)

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Dulaglutide (Trulicity)

Quick Facts: Dulaglutide (Trulicity)

  • Best Evidence:Grade A
  • Conditions Studied:2
  • Research Outcomes:19
  • Grade A Findings:8
  • Grade B Findings:4
  • Key Effect:Type 2 Diabetes
A8
B4
C4
D3
2 conditions · 19 outcomes

Detailed Outcomes

|
A
HbA1c Reduction
AWARD trials showed HbA1c reductions of 1.10-1.77% depending on dose. AWARD-5 showed 1.10% reduction with 1.5mg vs 0.39% with sitagliptin.
large↓Improves
A
Glycemic Control (HbA1c <7%)
AWARD trials showed higher proportions reaching HbA1c <7% and ≤6.5% vs comparators including sitagliptin, exenatide, and insulin glargine.
large↑Worsens
A
Body Weight Reduction
REWIND showed 1.5kg greater weight loss vs placebo sustained over 5.4 years. AWARD trials showed weight loss vs weight-neutral or weight-gaining comparators.
moderate↓Improves
A
Fasting Plasma Glucose
AWARD trials showed significant reductions in fasting plasma glucose across all studies vs comparators.
large↓Improves
A
Postprandial Glucose
AWARD-CHN2 analysis showed dulaglutide reduces both fasting and postprandial glucose components of HbA1c.
moderate↓Improves
A
Major Adverse Cardiovascular Events (MACE)
REWIND trial (9,901 patients) showed 12% reduction in MACE (HR 0.88, P=0.026) over median 5.4 years, the longest GLP-1 RA CV outcomes trial.
moderate↓Improves
A
Non-fatal Stroke
REWIND showed significant reduction in non-fatal stroke as component of MACE primary endpoint.
moderate↓Improves
A
Systolic Blood Pressure
REWIND showed 1.7 mmHg reduction in systolic blood pressure sustained over median 5.4 years follow-up.
small↓Improves
B
Blood Glucose Control
63 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
moderate↓Improves
B
Safety/Tolerability
19 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
moderate↑Improves
B
Kidney Function
7 human trials support this finding. Human clinical trial data available.
small↑Improves
C
Neuroprotection
5 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
C
Endothelial Function
4 human trials support this finding. Human clinical trial data available.
small↑Improves
C
Liver Protection
4 human trials support this finding. Human clinical trial data available.
small↑Improves
C
Anti-Inflammatory Activity
3 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
D
Cognitive Function
2 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
D
Cancer Cell Apoptosis
2 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
D
Anti-Cancer Activity
2 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves

Research Citations (67)

Dulaglutide markedly prevents peritoneal fibrosis in a rodent model of chronic kidney disease: Insights into the pathogenesis.
(2025)
PMID: 40709382
GIPR-Ab/GLP-1 peptide-antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice.
(2025)
PMID: 40301582
Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis.
(2025)
PMID: 40479843
Exploring Connections Between Weight-Loss Medications and Thyroid Cancer: A Look at the FDA Adverse Event Reporting System Database.
(2025)
PMID: 40055991
Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial.
(2025)
PMID: 40183678
Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials.
(2025)
PMID: 40212008
Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review.
(2025)
PMID: 40284168
Efficacy, Safety, and Future of GLP-1 Receptor Agonists: A Systematic Literature Review and Meta-Analysis.
(2025)
PMID: 40409279
Efficacy and Safety of Glucagon-Like Peptide-1 Agonists for Psychiatric Symptoms: A Systematic Review.
(2025)
PMID: 40635383
Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial.
(2025)
PMID: 40854315

Related Peptides

Tirzepatide (Mounjaro/Zepbound)

Peptide

2 shared conditions · 17 outcomes

Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). It is a 39-amino-acid synthetic peptide based on the native GIP sequence with a C20 fatty diacid modification enabling once-weekly dosing. The SURPASS and SURMOUNT clinical trial programs demonstrated unprecedented efficacy for glycemic control and weight loss, with up to 22.5% body weight reduction.

Semaglutide (Ozempic/Wegovy)

Peptide

2 shared conditions · 17 outcomes

Semaglutide is a GLP-1 receptor agonist peptide approved by the FDA for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). It is a 31-amino-acid peptide analog of human GLP-1 with 94% structural similarity but modified for extended half-life (approximately 1 week). The STEP, SUSTAIN, and SELECT clinical trial programs demonstrated consistent, substantial benefits for glycemic control, weight loss, and cardiovascular outcomes.